Pipeline
Our focus on new product development for musculoskeletal pain and pain adjacencies is motivated by the significant need for innovation in this space.
Developing better solutions to pain relief
We refuse to settle for therapies that are just “good enough.” Patients deserve better solutions that will not only help them get back to normal but remove the daily interferences caused by pain. Precise, targeted treatments have the potential to transform how pain is managed, and Pacira is at the forefront of this shift.
Our growing pipeline builds on our legacy of best-in-class, locally administered, long-acting, opioid-sparing therapies. From expanding proven solutions to investing in breakthroughs like gene therapy, we are committed to delivering medicine where it matters most.
Better
is Possible.
PCRX-201: Unlocking gene therapy to address pain
Osteoarthritis of the knee (OAK) is a serious disease in desperate need for innovation. PCRX-201 (enekinragene inzadenovec) is a gene therapy specifically designed to inhibit activation of inflammation caused by this disease and deliver more durable pain relief.
Let’s innovate together
Collaboration drives progress, and we’re proud to work with organizations that share our vision for advancing pain management.